All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Optimizing bridging therapies to CAR-T for children and young adults with R/R ALL
Bookmark this article
|
CAR T-cell therapies have emerged as an effective treatment option for patients with R/R B-ALL. In the period between CAR T-cell eligibility and infusion, disease progression poses a significant risk, necessitating the use of bridging therapy to optimize outcomes.1 High-intensity bridging therapies are often used in patients with a higher tumor burden; however, their potential benefits need to be evaluated against increased treatment-related toxicities. The impact of different bridging therapies prior to anti-CD19 CAR T-cell infusion was evaluated in a multinational retrospective study, comparing no systemic therapy, low-intensity, and high-intensity therapy in terms of OS, PFS, tumor burden, and adverse events in children and young adults (N = 88) with R/R B-ALL.1 Results from this analysis were published in the Journal of Hematology and Oncology by Breidenbach et al.1 |
| Key learnings |
| OS was significantly improved in patients who received no bridging therapy compared to those who received low- (p = 0.0297) or high-intensity (p = 0.0307) bridging therapy. There was no significant difference in PFS among the groups. |
| Patients who received high-intensity bridging therapy experienced increased adverse events, including a higher rate of bacterial infections (p = 0.0052) and mucositis (p= 0.0108). |
| Patients receiving high-intensity bridging therapy had a higher tumor burden and higher MRD at baseline compared to the low-intensity/no therapy group. |
| These data suggest that low-intensity bridging may be preferable when clinically feasible, particularly in patients with manageable tumor burden; necessitating prospective studies to optimize bridging therapy in R/R B-ALL. |
Abbreviations: B-ALL, B-cell lineage acute lymphoblastic leukemia; CAR, chimeric antigen receptor; MRD, measurable residual disease; OS, overall survival; PFS, progression-free survival; R/R, relapsed/refractory.
- Breidenbach M, Bader P, Attarbaschi A, et al. Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults. J Hematol Oncol. 2025;18(1):8. DOI: 1186/s13045-024-01659-x
More about...
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox